Remarks will focus primarily on data from the Phase 2b study of LY3298176, a GIP and GLP-1 dual receptor agonist.
INDIANAPOLIS, Sept. 6, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Thursday, October 4, 2018 to discuss the company's presentations at the 54th annual meeting of the European Association for the Study of Diabetes (EASD) in Berlin, Germany. Remarks will focus primarily on data from the Phase 2b study of LY3298176, a GIP and GLP-1 dual receptor agonist. The webcast will begin at 7 p.m. Central European Time, or 1 p.m. Eastern Time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/events.cfm. A replay will also be available on the website following the conference call. About Eli Lilly and Company Refer to: Mark Taylor; mark.taylor@lilly.com; (317) 276-5795 (Media) Kevin Hern; hern_kevin_r@lilly.com; (317) 277-1838 (Investors)
View original content with multimedia:http://www.prnewswire.com/news-releases/lilly-announces-webcast-to-discuss-easd-presentations-300707619.html SOURCE Eli Lilly and Company |
Company Codes: NYSE:LLY |